Intuitive Surgical stock steadies on $2.89 billion quarter
Published on 08/28/2026 at 06:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Intuitive Surgical, Inc. (US46120E6023) is trading on a valuation backdrop that still centers on a $131.97 billion market cap, a $371.67 Nasdaq close on August 25, 2026, and a 52-week range of $328.57 to $603.88. The latest Q2 2026 report showed $2.89 billion in revenue and $2.80 in EPS, up from $2.19 a year earlier, giving the shares a fresh numbers-first reference point.
Q2 scale stays visible
Per the recent sector overview dated August 26, 2026, Intuitive Surgical posted $2.89 billion in second-quarter revenue, an 18.5% increase year over year, while EPS climbed to $2.80 from $2.19. The same update said instruments and accessories revenue rose 18% to $1.73 billion, a useful sign that recurring utilization still drives the model.
Analyst estimates compiled on August 27, 2026 point to $2.61 in EPS for the current quarter and $11.77 billion in revenue for 2026, which frames the latest reported quarter against a still-strong full-year view. That is a smaller earnings pace than the 27.9% EPS jump seen in Q2 2026, so the comparison now matters more than the headline beat alone.
Procedure growth matters
The same August 26, 2026 overview said Q2 2026 procedure volume grew 15% and da Vinci system placements increased to 468 from 395 a year earlier. It also said the installed base reached 11,710 systems worldwide, up 12%, which is the kind of base expansion that can keep instrument and service revenue compounding.
For investors, the key detail is that recurring revenue is doing more of the work. In the first quarter of 2026, recurring revenue reached $2.4 billion and represented 86% of sales, while Q2 instruments and accessories revenue already accounted for about 60% of quarterly revenue at $1.73 billion.
Da Vinci remains central
The da Vinci platform remains the core of the business, and the latest operating figures show why. Q1 2026 procedures grew 17%, including 16% growth in da Vinci procedures and 39% growth in Ion procedures, before Q2 2026 extended the broader procedure increase to 15%.
That mix also helped margins. Recent data cited non-GAAP gross margin of 67.8% in Q1 2026, up from 66.4% a year earlier, while first-half 2026 free cash flow reached $1.8 billion and cash and investments stood at $8.6 billion.
Current stock level
Intuitive Surgical stock closed at $371.67 on August 25, 2026, and the latest quote snapshot put it at $367.33, with market cap at $133.2 billion and volume at 949.3K shares. The shares remain well below the $603.88 52-week high, but the quarter's revenue, EPS, and procedure figures keep the fundamental picture active.
More on Intuitive Surgical
Intuitive Surgical sells robotic-assisted surgical systems led by da Vinci, plus Ion and a broad stream of instruments, accessories, and service revenue tied to procedure volume. That structure is why the company's installed base, recurring sales mix, and quarterly procedure growth remain the most important numbers to watch.
Fact box
Company: Intuitive Surgical, Inc.
ISIN: US46120E6023
Ticker: ISRG
Exchange: Nasdaq
Price (as of August 28, 2026): $367.33 USD
Market cap: $133.2 billion (as of August 28, 2026)
Sector / Industry: Health Care Equipment and Supplies
Index membership: S&P 500
